Glioblastoma Multiforme Treatment Market (By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy; By Drug Class: TMZ, Carboplatin, Cisplatin, Bevacizumab, Others; By End-user: Hospitals, Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Glioblastoma Multiforme Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Glioblastoma Multiforme Treatment Market, by Treatment, 2024-2033
8.1.1 Surgery
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Radiation Therapy
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Tumor Treating Field (TTF) Therapy
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Immunotherapy
8.1.6.1. Market Revenue and Forecast (2021-2033)
9.1. Glioblastoma Multiforme Treatment Market, by Drug Class, 2024-2033
9.1.1. TMZ
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Carboplatin
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Cisplatin
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Bevacizumab
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
10.1. Glioblastoma Multiforme Treatment Market, by End-user, 2024-2033
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Ambulatory Surgical Centers
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.3. Market Revenue and Forecast, by End-user (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.3. Market Revenue and Forecast, by End-user (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.3. Market Revenue and Forecast, by End-user (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.3. Market Revenue and Forecast, by End-user (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.3. Market Revenue and Forecast, by End-user (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.3. Market Revenue and Forecast, by End-user (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.3. Market Revenue and Forecast, by End-user (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.3. Market Revenue and Forecast, by End-user (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.3. Market Revenue and Forecast, by End-user (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.3. Market Revenue and Forecast, by End-user (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.3. Market Revenue and Forecast, by End-user (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.3. Market Revenue and Forecast, by End-user (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.3. Market Revenue and Forecast, by End-user (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.3. Market Revenue and Forecast, by End-user (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.3. Market Revenue and Forecast, by End-user (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.3. Market Revenue and Forecast, by End-user (2021-2033)
12.1. Merck & Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Amgen, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Teva Pharmaceutical Industries Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sun Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arbor Pharmaceuticals, LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Amneal Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Karyopharm Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample